Drug Profile
Tagitanlimab - Harbour BioMed/Sichuan Kelun Pharmaceutical Research Institute
Alternative Names: A-167; HBM-9167; KL-A167Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Sichuan Kelun Pharmaceutical Research Institute
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Solid tumours
- Phase II Breast cancer; Hodgkin's disease; Nasopharyngeal cancer
- No development reported Colorectal cancer; Lung cancer; Lymphoma; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Aug 2022 No recent reports of development identified for preclinical development in Non-Hodgkin's-lymphoma in China (IV, Injection)
- 04 Jul 2022 Preregistration for Solid tumours in China (IV) (Klus Pharma pipeline, July 2022)
- 04 Apr 2022 Sichuan Kelun Pharmaceutical plans a phase III trial for Nasopharyngeal Cancer (Combination therapy, Metastatic disease, Recurrent) in June 2022 (NCT05294172)